四逆散合桂枝甘草龙骨牡蛎方治疗多囊卵巢综合征合并昼夜节律失调的临床效果

doi:10.3969/j.issn.1006-5725.2026.05.010

Abstract

Abstract:

Objective To observe the clinical efficacy of Sini powder combined with Guizhi Gancao Longgu Muli decoction in the treatment of polycystic ovary syndrome （PCOS） accompanied by circadian rhythm disorder. Methods A total of 102 patients diagnosed with PCOS and comorbid circadian rhythm disorder， who received treatment at Shanxi Bethune Hospital from March 2023 to March 2025， were randomly assigned to either an observation group or a control group using a random number table， with 51 cases in each group. The control group received Diane-35 along with lifestyle intervention， whereas the observation group was additionally treated with modified Sini powder combined with Guizhi Gancao Longgu Muli decoction. Both groups underwent treatment for three consecutive menstrual cycles. The clinical efficacy was compared between the two groups. Moreover， changes in traditional Chinese medicine syndrome scores， endocrine hormones， glucose and lipid metabolism indices， sleep quality， and circadian rhythm indicators were evaluated both before and after the treatment. Adverse reactions were also documented. Results The total effective rate in the observation group （96.08%） was significantly higher than that in the control group （80.39%）（P < 0.05）. After treatment， the observation group showed lower scores of Traditional Chinese Medicine （TCM） syndromes， luteinizing hormone （LH）， LH/follicle-stimulating hormone （FSH） ratio， testosterone （T）， anti-Müllerian hormone （AMH）， fasting blood glucose （FBG）， fasting insulin （FINS）， homeostasis model assessment of insulin resistance （HOMA-IR）， triglyceride （TG）， total cholesterol （TC）， cortisol （COR）， and Pittsburgh Sleep Quality Index （PSQI） scores compared to the control group （P < 0.05）. In contrast， the levels of follicle-stimulating hormone （FSH） and melatonin （MT） were higher in the observation group than in the control group （P < 0.05）. There was no statistically significant difference in the incidence of adverse reactions between the observation group （3.92%） and the control group （5.88%）（P > 0.05）. Conclusion Sini powder combined with Guizhi Gancao Longgu Muli decoction can effectively regulate sex hormone disorders， improve insulin resistance and abnormal lipid metabolism， and restore the normal sleep-wake rhythm.

Key words: polycystic ovary syndrome, circadian rhythm disorder, Sini powder, Guizhi Gancao Longgu Muli decoction, integrated Chinese-Western therapy

CLC Number:

R271.1

Zhenzhen CHANG,Jinquan WANG,Haihong CHENG. Clinical effect of Sini powder with Guizhi Gancao Longgu Muli decoction in the treatment of polycystic ovary syndrome with circadian rhythm disorder[J]. The Journal of Practical Medicine, 2026, 42(5): 801-806.

Figures/Tables 5

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

References 21

[1]	MATSUYAMA S， WHITESIDE S， LI S Y. Implantation and Decidualization in PCOS： Unraveling the Complexities of Pregnancy［J］. Int J Mol Sci， 2024， 25（2）： 1203-1205. doi： 10.3390/ijms25021203 . doi: 10.3390/ijms25021203
[2]	PINTO J， CERA N， PIGNATELLI D. Psychological symptoms and brain activity alterations in women with PCOS and their relation to the reduced quality of life： A narrative review［J］. J Endocrinol Invest， 2024， 47（7）： 1-22. doi： 10.1007/s40618-024-02329-y . doi: 10.1007/s40618-024-02329-y
[3]	AMIN S N， ASALI F， AOLYMAT I， et al. Comparing MitoQ10 and heat therapy： Evaluating mechanisms and therapeutic potential for polycystic ovary syndrome induced by circadian rhythm disruption［J］. Chronobiol Int， 2023， 40（8）：1004-1027. doi： 10.1080/07420528.2023.2241902 . doi: 10.1080/07420528.2023.2241902
[4]	LAFCI N G， YILMAZ B， YILDIZ B O. PCOS - the many faces of a disorder in women and men［J］. J Endocrinol Invest， 2025， 48（4）： 785-798. doi： 10.1007/s40618-024-02512-1 . doi: 10.1007/s40618-024-02512-1
[5]	SIDDIQUI S， MATEEN S， AHMAD R， et al. A brief insight into the etiology， genetics， and immunology of polycystic ovarian syndrome （PCOS）［J］. J Assist Reprod Genet， 2022， 39（11）： 2439-2473. doi： 10.1007/s10815-022-02625-7 . doi: 10.1007/s10815-022-02625-7
[6]	WAHID S， RAMLI M D C， FAZLEEN N E， et al. Exploring the Therapeutic Potential of Natural Products in Polycystic Ovarian Syndrome （PCOS）： A Mini-Review of Lipid Profile， Blood Glucose， and Ovarian Histological Improvements［J］. Life （Basel）， 2024， 14（1）： 150-153. doi： 10.3390/life14010150 . doi: 10.3390/life14010150
[7]	李荔，周嘉禾，李末娟，等. 多囊卵巢综合征表观遗传学、代谢组学、肠道菌群新机制前沿展望［J］. 实用医学杂志， 2022， 38（16）： 1987-1992. doi：10.3969/j.issn.1006-5725.2022.16.001 . doi: 10.3969/j.issn.1006-5725.2022.16.001
[8]	SHEN Z， YU M， DONG Z. Research Progress on the Pharmacodynamic Mechanisms of Sini Powder against Depression from the Perspective of the Central Nervous System［J］. Medicina （Kaunas）， 2023， 59（4）： 741-743. doi： 10.3390/medicina 59040741 . doi: 10.3390/medicina 59040741
[9]	中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南［J］. 中华妇产科杂志， 2018， 53（1）： 2-6. doi： 10.3760/cma.j.issn.0529-567x.2018.01.002 . doi: 10.3760/cma.j.issn.0529-567x.2018.01.002
[10]	SILVA G E， ROJO-WISSAR D M， QUAN S F， et al. Predictive ability of the International Classification of Sleep Disorders-3 in identifying risk of obstructive sleep apnea among recently unemployed adults［J］. Sleep Breath， 2021， 25（3）： 1325-1334. doi： 10.1007/s11325-020-02210-1 . doi: 10.1007/s11325-020-02210-1
[11]	国家中医药管理局. 中医病证诊断疗效标准［M］. 北京：中国医药科技出版社， 2012： 122-124.
[12]	SHRIVASTAVA S， CONIGLIARO R L. Polycystic Ovarian Syndrome［J］. Med Clin North Am， 2023， 107（2）： 227-234. doi： 10.1016/j.mcna.2022.10.004 . doi: 10.1016/j.mcna.2022.10.004
[13]	郭倩，陈婕，李晓欣，等. 从子午流注学说探讨多囊卵巢综合征的治疗［J］. 南京中医药大学学报， 2024， 40（7）： 661-667. doi： 10.14148/j.issn.1672-0482.2024.0661 . doi: 10.14148/j.issn.1672-0482.2024.0661
[14]	周洁，张慧丽，王旭东. 理痰汤加味联合八段锦对多囊卵巢综合征胰岛素抵抗的影响［J］. 辽宁中医杂志， 2025， 52（8）： 103-108. doi： 10.13192/j.issn.1000-1719.2025.08.026 . doi: 10.13192/j.issn.1000-1719.2025.08.026
[15]	孙六娜，卢如玲，张淑婷，等. 寿胎丸对肾虚型多囊卵巢综合征不孕患者子宫内膜容受性及相关因子的影响［J］. 实用医学杂志， 2023， 39（3）： 355-359. doi： 10.3969/j.issn.1006-5725. 2023.03.016 . doi: 10.3969/j.issn.1006-5725. 2023.03.016
[16]	薄晓莉，潘静，冷静，等. 石英毓麟汤加减对肾虚血瘀型多囊卵巢综合征患者免疫调控，抗缪勒管激素，促卵泡生成素水平的影响［J］. 中华中医药学刊， 2024， 42（5）： 156-159. doi： 10.13193/j.issn.1673-7717.2024.05.031 . doi: 10.13193/j.issn.1673-7717.2024.05.031
[17]	SALEHI S， ALLAHVERDY J， POURJAFAR H， et al. Gut Microbiota and Polycystic Ovary Syndrome （PCOS）： Understanding the Pathogenesis and the Role of Probiotics as a Therapeutic Strategy［J］. Probiotics Antimicrob Proteins， 2024， 16（5）： 1553-1565. doi： 10.1007/s12602-024-10223-5 . doi: 10.1007/s12602-024-10223-5
[18]	ZHU T， GOODARZI M O. Causes and Consequences of Polycystic Ovary Syndrome： Insights From Mendelian Randomization［J］. J Clin Endocrinol Metab， 2022， 107（3）： 899-911. doi： 10.1210/clinem/dgab757 . doi: 10.1210/clinem/dgab757
[19]	NI F， WANG F， SUN J， et al. Proteome-wide Mendelian randomization and functional studies uncover therapeutic targets for polycystic ovarian syndrome［J］. Am J Hum Genet， 2024， 111（12）： 2799-2813. doi： 10.1016/j.ajhg.2024.10.008 . doi: 10.1016/j.ajhg.2024.10.008
[20]	ISMAIL A B， NAJI M S， NEBIH İ， et al. The expression profile of WNT/β-catanin signalling genes in human oocytes obtained from polycystic ovarian syndrome （PCOS） patients［J］. Zygote， 2022， 30（4）： 536-542. doi： 10.1017/S0967199422000028 . doi: 10.1017/S0967199422000028
[21]	VOROS C， ATHANASIOU D， PAPAPANAGIOTOU I， et al. Molecular Shadows of Per- and Polyfluoroalkyl Substances （PFASs）： Unveiling the Impact of Perfluoroalkyl Substances on Ovarian Function， Polycystic Ovarian Syndrome （PCOS）， and In Vitro Fertilization （IVF） Outcomes［J］. Int J Mol Sci， 2025， 26（14）： 6604. doi： 10.3390/ijms26146604 . doi: 10.3390/ijms26146604

组别	例数	显效	有效	无效	总有效率/%
观察组	51	29（56.86）	20（39.22）	2（3.92）	96.08
对照组	51	16（31.37）	25（49.02）	10（19.61）	80.39
χ²值					6.044
P值					0.014

组别	例数	月经后期/闭经		烦躁易怒		失眠多梦		心悸不安
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	51	2.63 ± 0.21	0.81 ± 0.28	2.37 ± 0.34	0.73 ± 0.26	2.52 ± 0.35	0.88 ± 0.31	2.24 ± 0.52	0.62 ± 0.23
对照组	51	2.59 ± 0.23	1.54 ± 0.52	2.34 ± 0.28	1.39 ± 0.41	2.50 ± 0.41	1.76 ± 0.59	2.18 ± 0.55	1.25 ± 0.37
t值		0.917	8.827	0.486	9.708	0.265	9.429	0.566	10.327
P值		0.361	< 0.001	0.628	< 0.001	0.792	< 0.001	0.573	< 0.001

组别	例数	LH/（mIU/mL）		FSH/（mIU/mL）		LH/FSH		T/（ng/mL）		AMH/（ng/mL）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	51	13.82 ± 3.15	6.17 ± 1.93	5.31 ± 1.18	6.59 ± 1.24	2.60 ± 0.57	0.94 ± 0.28	0.81 ± 0.19	0.42 ± 0.11	9.74 ± 2.16	5.28 ± 1.57
对照组	51	13.59 ± 3.41	8.94 ± 2.16	5.46 ± 1.25	5.92 ± 1.08	2.49 ± 0.62	1.51 ± 0.39	0.79 ± 0.21	0.58 ± 0.14	9.58 ± 2.33	7.16 ± 1.84
t值		0.354	6.829	0.623	2.910	0.933	8.479	0.504	6.418	0.360	5.551
P值		0.724	< 0.001	0.535	0.005	0.353	< 0.001	0.615	< 0.001	0.720	< 0.001

组别	例数	FBG/（mmol/L）		FINS/（mU/L）		HOMA-IR		TG/（mmol/L）		TC/（mmol/L）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	51	5.18 ± 0.49	4.79 ± 0.36	17.42 ± 4.26	9.15 ± 2.88	4.19 ± 1.12	1.93 ± 0.64	1.93 ± 0.58	1.22 ± 0.41	5.29 ± 0.83	4.37 ± 0.62
对照组	51	5.25 ± 0.52	5.01 ± 0.42	17.68 ± 4.51	13.57 ± 3.19	4.31 ± 1.27	3.16 ± 0.81	1.89 ± 0.61	1.58 ± 0.49	5.34 ± 0.80	4.88 ± 0.69
t值		0.700	2.840	0.299	7.345	0.506	8.509	0.339	4.024	0.310	3.926
P值		0.86	0.006	0.765	< 0.001	0.614	< 0.001	0.735	< 0.001	0.757	< 0.001

组别	例数	PSQI/分		MT/（pg/mL）		COR/（nmol/L）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	51	13.18 ± 2.07	5.94 ± 1.51	48.26 ± 9.11	81.47 ± 10.22	512.41 ± 55.18	388.29 ± 46.37
对照组	51	12.92 ± 2.24	9.27 ± 1.85	49.03 ± 8.95	62.19 ± 9.58	506.81 ± 58.24	451.76 ± 50.11
t值		0.609	9.958	0.431	9.829	0.498	6.639
P值		0.544	0.001	0.668	< 0.001	0.619	< 0.001

Clinical effect of Sini powder with Guizhi Gancao Longgu Muli decoction in the treatment of polycystic ovary syndrome with circadian rhythm disorder

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 21

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	Yunhong JIAO,Weiliang ZHANG,Wei SONG. The diagnostic value of serum chemerin/visfatin ratio for insulin resistance in PCOS patients [J]. The Journal of Practical Medicine, 2026, 42(4): 564-570.
[2]	Yuancheng LI,Li. LI. Androgen‑mediated DGAT2 upregulation promotes ferroptosis in granulosa cells in polycystic ovary syndrome [J]. The Journal of Practical Medicine, 2025, 41(16): 2498-2506.
[3]	Yanzhi WU,Yang. LIU. Research progress of m6A modification in benign ovarian related diseases [J]. The Journal of Practical Medicine, 2024, 40(16): 2352-2356.
[4]	SUN Liuna, LU Ruling, ZHANG Shuting, LI An, LAN Hon⁃ gyun, HE Yanxia, JIANG Yong.. Effects of Shoutai Pill on endometrial receptivity and related factors in infertile patients with polycystic ovary syndrome induced by kidney deficiency [J]. The Journal of Practical Medicine, 2023, 39(3): 355-359.
[5]	ZHANG Ying, LIU En.. Clinical diagnosis，treatment and progress of non ⁃ classical 21 hydroxylase deficiency [J]. The Journal of Practical Medicine, 2023, 39(1): 1-5.
[6]	LI Li, ZHOU Jiahe, LI Mojuan, ZHONG Minglin, ZHANG Xiaowei, XU Qiuyi, LIANG Li⁃ anyun.. A frontier review and an outlook on epigenetics，metabolomics，and gut microbiota mechanism of polycystic ovary syndrome [J]. The Journal of Practical Medicine, 2022, 38(16): 1987-1992.
[7]	TAN Qiuxiao, ZHANG Hongmei, LI Jieming, CHEN Zhijing, ZHANG Xiaowei, LI Li. Prevalence and influencing factors of depression and anxiety in patients with polycystic ovary syndrome [J]. The Journal of Practical Medicine, 2020, 36(23): 3288-3292.